The safety of testosterone supplementation therapy in prostate cancer
This review challenges the longstanding belief that testosterone supplementation therapy (TST) exacerbates prostate cancer (PCa). The “saturation model” posits that prostate androgen receptors are fully activated at serum testosterone levels of 150–200 ng/dL, beyond which additional testosterone has minimal effect on prostate tissue. Contemporary studies indicate that TST does not
June 26, 2025
No Comments